| Objective:To evaluate the clinical efficacy and safety of bortezomib combined with Dujieqing oral liquid solution in Multiple Myeloma(MM)with spleen and kidney deficiency and combined syndrome of toxic stasis,and to evaluate the relationship between clinical efficacy and serum IL-6 and STAT3.Methods: From January 2017 to September 2018,60 patients admitted to the hematology department of the first affiliated hospital of guangxi university of traditional Chinese medicine who were diagnosed with multiple myeloma by western medicine and multiple myeloma(spleen and kidney deficiency,toxic blood stasis)by traditional Chinese medicine were selected.All patients were divided into two groups by random number table method,30 cases in each group.The control group was treated with borotezomib chemotherapy regimen,and the treatment group was treated with borotezomib chemotherapy regimen combined with dujieqing oral liquid(20ml tid)orally for a course of 35 days.Four evaluation after treatment,observing two groups of patients before and after treatment clinical Overall response Rate(Overall Reaction Rate,ORR),serum free light chain kappa,lambda predominate(serum free light chain kappa,lambda,predominate sFLC kappa,lambda)predominate,M protein and plasma cell proportion,the Overall efficacy of traditional Chinese medicine,single TCM syndrome integral,serum IL-6,serum levels of STAT3 and Adverse reactions,(Adverse Effect,AE)rates.Results:1.Comparison of efficacy between the two groups:(1)clinical efficacy of western medicine:ORR of patients in the two groups after treatment: ORR of the control group was 64.29%;The ORR of the treatment group was 75.86%,and the overall efficacy of the treatment group was better than that of the control group(P<0.05).(2)overall efficacy of TCM syndromes: the effective rates of the control group and the treatment group were 64.29% and 89.66% respectively,and the treatment group was superior to the control group(P<0.05).2 comparison of efficacy indicators between the two groups:(1)the ratio of sFLC(kappa,lambda),M protein and plasma cell count after treatment was lower in the two groups than before treatment,and the treatment group was superior to the control group(P<0.05).(2)The TCM syndromes of patients in the two groups,such as fatigue and fatigue,eating less and eating less,body wasting,dizziness and tinnitus,were all improved,and the numbness scores of the limbs were increased.The therapeutic effect of the two groups was better than that of the control group(P< 0.05).3.Specific indicators:serum IL-6 and STAT3 decreased in both groups after treatment(P<0.05),and the treatment group was superior to the control group.4 Two groups of patients with adverse reaction and safety observation indexes: the control group adverse reactions occurred a total of 14 cases,4 cases were nausea and vomiting,liver function damage in 2 cases and lung infection of 8 cases respectively,the incidence of adverse reactions was 50.0%,the treatment group in a total of 13 cases,4 cases were nausea and vomiting,liver function damage in 2 cases,pulmonary infection in 7 cases,the incidence of adverse reactions was 44.83%.Conclusion:1.The treatment of MM with dujieqing oral liquid combined with boron tezoumi chemotherapy regimen can effectively improve the ORR of patients in western medicine and reduce the ratio of sFLC(kappa,lambda),M protein and plasma cells.To improve the curative effect of TCM syndromes,reduce the syndrome points of fatigue and fatigue,eating less and eating less,body wasting,dizziness and tinnitus,and delay the aggravation of limb numbness.2.Dujieqing oral liquid combined with bortezomib can reduce serum IL-6 and STAT3 levels,and the improvement of clinical efficacy may be related to the decrease of serum IL-6 and STAT3 levels.3.Dujieqing oral liquid combined with borotezomib chemotherapy is safe and effective,without increasing adverse reactions in patients. |
PDF Full Text Request